Introduction

The history behind miRNAs: how, why, when and where?
In 1998, Fire and Mello observed for the first time that double-stranded RNA (dsRNA) was the main cause of sequence-specific inhibition of protein expression in Caenorthabditis elegans, which they called the "RNA interference" (RNAi) pathway [1] . It became evident that RNAi is critical to the control of post-transcription gene silencing in widely dispersed eukaryotic forms from yeast, fungi, plants, and animals [2, 3] . To date, three major types of noncoding RNAs have been identified as RNAi effectors: small interfering RNAs (siRNAs), microRNAs (miRNAs) and piwi-interacting RNAs (piRNAs) [4] . microRNAs are small endogenous non-coding RNA molecules (20-23 nucleotides) derived from imperfectly paired hairpin RNA structures naturally encoded in the genome [5] that act specifically as triggering molecules to control translational repression or mRNA degradation. They regulate 10-30% of all protein-coding genes, targeting amino acid coding sequences [6] , as well as promoters of gene expression [7] and long-non-coding RNAs [8, 9] . This remarkable machinery involved in gene regulation processes is evolutionarily conserved and involved in many biological processes such as cell proliferation, differentiation, apoptosis, metabolism, development, ageing and cancer. Moreover, miRNAs are key players in reinforcing molecular networks, acting as "genetic buffers", minimizing the noise of floppy cellular transcription regulation [10, 11] . miRNA biogenesis arises in the cell's nucleus and encompasses numerous RNA processing steps (Figure 1) . miRNA coding genes are generally transcribed by RNA polymerase II (Pol II) (from polycistronic transcripts, or introns of protein-coding genes) within the nucleus, producing large (several thousand bases in length) capped and polyadenylated pri-miRNA transcripts. These primiRNA transcripts are processed by the RNase III enzyme Drosha to generate ~70-90 nt long precursor miRNA (pre-miRNA). pre-miRNAs present an imperfect stem-loop hairpin structure and are transported from the nucleus into the cytoplasm by the exportin 5 enzyme. After Dicer processing the precursor miRNA is transformed into a transient 22 nt mature double stranded (ds) miRNA (miR:miR duplex). The Dicer also processed the unwinding of these miRNA duplexes and promotes the incorporation of one strand of the duplex into a miRNA-associated RNA-induced silencing complex (miRISC) and a multi-protein complex that includes Dicer and proteins from the Argonaute family. The mature miRNA guides RISC to target mRNAs and or proteins, promoting their degradation [12, 13] . In animals, partial complementarity (in Mammalia, the miRNAs rarely have a perfect complementarity with their targets) between mature miRNA and mRNA leads to an endonucleolytic cleavage, catalyzed by the human Ago2 in the RISC. Translational repression occurs without endonucleolytic cleavage, contrary to their "close relative" siRNA. Polymerase II (POL II) produces pri-miRs, transcribed from miRNA genes. Pri-miRNAs are then processed and catalyzed by DROSHA (RNase III type endonuclease) that processes pri-miRNAs to pre-miRNAs. After nuclear exportation (via Exportin5), DICER processes pre-miRNAs into 20-bp miR:miR duplexes. After miRNA duplex unwinding by the DICER, one strand is selected to function as mature miR and loaded into the RISC (RNA-induced silencing complex) and to the Argonaute family (specially, AGO2). The partner miR strand is degraded. The mature miR may lead to mRNA degradation or translational repression, as well as protein downregulation.
The mechanism described above is the accepted pathway for miRNA biogenesis; however recent studies have reported several alternative pathways, which depend on cell type, organism and biological contexts [14, 15] .
miRNAs: the Jack-of-all-trades or the Master of none?
miRNAs' small size and lack of poly-A tails may have kept them out of the spotlight for decades, however it is thought that the human genome may contain up to one thousand miRNA genes, which could regulate one third of our protein-coding genes. Actually, there is more to miRNA than meets the eye. Almost 40 years after the discovery of RNA, there is a growing evidence that these small endogenous dsRNA are just as potent as many transcription factors and can regulate the expression of a specific gene, and hence a protein. The concept is simple: miRNAs recognize a complementary sequence encoded in a specific messengerRNA (mRNA) and bind to it, interfering with the correct translation of the mRNA sequence, impairing protein production.
Of course ascribing the silencing of genes solely to the existence of miRNA is short-sighted. In reality, these major players need a battery of enzymes to meet their ends like Drosha and Dicer, whose major role is to recognize and cleave mRNA [16] . Contrary to plant miRNAs whose sequences match with a great precision to their complementary RNA targets, animal miRNAs are far more promiscuous. The binding procedure is far less accurate and demanding as miRNAs can bind to as many as one hundred different sequences. This may sound economical and cost-effective nature-wise, however their use in laboratory makes things far more tricky and delicate, as unique miRNA may regulate numerous genes and be involved in many cellular pathways and the fact propensity of animal miRNAs to degradation makes them difficult to use as diagnostic biomarkers or for therapeutic applications. miRNAs are gaining recognition as critical regulators of many biological processes, emerging as therapeutic targets for treating disease and yet there are significant challenges to clinical utility in particular in delivering these compounds effectively. We will review the state of nanocarrier technology for miRNA and its role in translating miRNA into the clinic.
miRNAs in Cancer
Despite a quarter of century of rapid technological advances, cancer is still a major cause of mortality in the modern world, with more than 10 million new cases every year. In fact, around one in three people will be diagnosed with cancer throughout their lifetime [17] . Although we have been generating a solid and complex knowledge, revealing cancer as a disease intimately involved in the dynamic change of the genome, some continue to argue that the search for the origin and treatment of this disease will continue throughout the next quarter of the century, requiring far greater insight than we have now [18] . Cancer treatment is improving and extending patients' survival worldwide. However, traditional cancer treatment protocols lack selectivity towards cancer cells and hence adversely affect adjacent healthy tissue. Additionally, inhibition of growth and development of blood cell lineages may ultimately lead to increased susceptibility to secondary infections. Still, many clinical chemotherapeutic and radiotherapeutic regimes are not very effective, due to chemo-and radioresistance, and is patient and tumor type-dependent. Therefore, there is an urgent need for superior and more effective cancer therapies [19] .
Cancer gene therapy is receiving increasing attention and could represent an attractive approach for novel treatment or prevention of many diseases where conventional clinical procedures have poor efficacy. There are two general abnormalities in cancer cells to take into account: i) they exhibit deregulation of the cell cycle resulting in uncontrolled growth; and ii) they are resistant to death as result of abnormalities in one or more proteins that inhibit apoptosis [20] . Among these, abnormally expressed microRNAs (miRNAs) have been increasingly considered as triggers of tumor development.
Abnormal gene expression can be regulated at either the transcriptional or post-transcriptional level, where miRNAs are available for sequence-specific gene silencing and regulation [21] . In fact, the significance and power of the so-called oncomiRs in the tumorigenic process has been gaining momentum in cancer research [22, 23] .
It is well known that abnormal miRNA expression is intimately associated with cancer establishment and progression, having a fundamental role in cancer. Consequently, the use of miRNA tumor suppressors or their oncomiRs might serve as useful therapeutic molecules. In fact, the combinatorial miRNA therapeutics using both tumor supressors and oncomiRs inhibitors will probably follow, as the therapeutic potential of specific miRNAs is discovered. Moreover, targeting a specific coding gene with multiple miRNA tumor suppressors may enhance the therapeutic effect and thus, reducing the occurrence of resistance mechanisms. This is the beauty of miRNAs  the possibility of multitargeting, even within a single pathway. Though natural (or artificial) single point mutation in the untranslated region of an oncogene may impair the specific binding of a particular miRNA, the combination of several miRNAs targeting the same gene sequence would decrease the probability of mutation-induced resistance. The same happens for the simultaneous targeting of upregulated miRNAs using antagomiRs, as well as the replacement of lost tumor suppressor miRNAs [24] .
However, the utility of miRNAs in cancer diagnosis and treatment will strongly depend on the careful design of an ideal vector, capable of fulfilling the delivery of a therapeutic gene to as many cells as possible in a highly specific way, achieving the appropriate levels of gene expression [21, 25] . The highly effective vectors render serious doubts about safety for animal or human usage and others know as safe are not efficient enough.
miRNA sensing
As modification in miRNA profiles are intimately linked to different states of cancer and can be used as important biomarkers for cancer diagnostics, many technologies have been developed to detect the presence and changes in miRNA expression levels [26] [27] [28] . Presently, most of the miRNA sensing studies are using techniques such as Northern blot for miRNA expression patterns. Many different approaches have been exploited to profile mature miRNAs expression, including deep-sequencing, quantitative PCR, in-situ hybridization or oligonucleotide microarrays. Nevertheless, these methodologies are relatively insensitive, time-consuming and labor intensive. It is extremely challenging to detect small RNAs (most of the times in low concentration) with standard techni ques [29] . So it is imperative to develop new techniques that allow easy monitoring of miRNA expression in a variety of biological sample types with substantially more sensitivity than Northern analysis.
The application of nanomaterials as platforms for optical and electrochemical sensing of miRNA has been gaining reputation in the field. discrimination of singlenucleotide [54] probe:microRNA duplexviral protein p19 miR122a; rat liver 1 pg uniform, robust and welldefined solid-state membrane for nanopore production; detection from biological tissue [55] Cy3-Cyanine dye; QDs-quantum dots; GO-Graphene Oxide; PNA-Peptide nucleic acid; FAM-Fluorescein.
Plasmonic/Optical-based miRNA sensors
The majority of DNA/RNA nanosensors are based on Watson-Crick base-pairing between complementary sequences. Although the binding of miRNAs to their targets depend largely on multiple factors (thermodynamic characteristics; seed sequence in hybrid formation) most of the optical miRNA sensors are based on pure DNA or RNA oligonucleotide hybridization with the targeted miRNA. These applications (see Table 1 ) rely on optical detection and usually use a large number of different types of fluorescent reporters, including organic dyes, fluorescent proteins or inorganic nanostructures, such as quantum dots or gold nanoparticles [56] . In fact, quantum dots are exceptional substitutes as fluorescence labels with narrow, tunable, symmetrical emission spectra, and high quantum yields [57] . This is particularly important in samples where miRNAs need to be enriched due to low concentration, once the high quantum emission of these nanostructures qualify them for direct detection applications [56] .
Gold nanoparticles have also been extensively used in miRNA detection using specially thiolated-DNA probes to hybridize with mature miRNAs, coupled to an avidin-biotin detection system. An inexpensive and easy alternative to fluorescence or radioactivity-based assays exploits the high affinity of thiol group to gold surface and the use of thiol-linked ssDNA-modified gold nanoparticles for colorimetric detection of gene targets [58, 59] . These systems are simple and efficient and can even diagnose a single nucleotide mismatch between miRNA members.
Graphene oxide (GO) 2D nanostructures (with excellent thermal, electronic and mechanical performances) have also been successfully applied to miRNA detection due to their distancedependent fluorescence quenching skills. They provide highly sensitive and specific signal, with detection limits comparable to surface-plasmon resonance (SPR) and fluorescence methodologies [56] . The optical-based methods using nanomaterials usually have a detection limit range from 0.1 aM to 1 pM (see Table 1 ). One of the most limitations of optical-based nanomaterials is that may produce high background signal due to quenching inefficiencies [60] .
Electrochemical miRNA sensing: labeled miRNA versus label free
Electrochemical methods have found numerous applications in sensing miRNA molecules, due to the development of fast, simple and sensitive methods with low detection limits (see Table 1 ). Moreover, electrochemical methods allow for miRNA sensing without enzymatic amplification. Typically, the detection and quantification of the miRNA target is based on measuring the change in voltage in the presence of a specific target miRNA [56] . In all electrochemical techniques, miRNA hybridizes to a complementary probe, which is immobilized on the surface of an electrode or nanoparticle [60] . These methods are particularly important to reduce the amounts of sample required and are usually fast and very sensitive and are divided into indirect (targeting labeled miRNA) and direct methods (label-free).
The labeled miRNA methods usually use a chemical tag that is bound to the target miRNA sequence, which upon miRNA hybridization to the probe will produce an amplification-signal to detect and quantify the levels of expression. Voltametric and electrocatalytic nanoparticles (specially made of ruthenium and osmium oxides) are frequently applied [61] and they readily bond to the hybridized miRNA and have high catalytic capacity [56] . Direct methods (using label-free miRNAs) are faster than indirect methods and are less prompt to bias. Most of the nanomaterials used are based on nanowires of silicon or polymer materials (eg. Polyaniline). As such they can be formed into supramolecular networks with high electrochemical capacities, that depend on electrochemical redox state, humidity, pH, presence and type of anions in solution, and temperature [56] . miRNA detection and quantification occurs through changes in the environment conductivity and charge of the formednanomaterials network by the presence of negatively charged phosphate groups from miRNAs.
Another interesting system is the nanopore-based sequencing techniques, which uses a nanoscale pore in a membrane between two electrolytes and voltage to drive molecules through the pore. Changes in the ionic current through the nanopore as single molecules (for example, miRNAs) pass through it can be monitored [62, 63] (see Figure 2) . These systems can be used for direct detection of circulating cancer miRNA biomarkers in plasma and tissue from mice [55] and cancer patients [54] . Although nanopore-based sequencing techniques have the potential to be direct this technology is not yet likely to be applied in any practical application, due to the difficulty in their fabrication, requiring highly qualified personnel and special equipment [56, 60] .
The electrochemical-based methods using nanomaterials usually have a detection limit range from 0.32 aM to 2 pM (see Table 1 ). The main disadvantages of electrochemical-based methods are in some cases complicated manufacturing of the devices (some are not even portable!), the inability of multiplexing and the cost [56] . 
miRNA therapeutics
miRNAs have emerged as master regulators in the expression of genes and as critical therapeutic agents in numerous disease states, such as cancer, inherited diseases, heart diseases and in the regulation of the nervous system [64] . One of the most remarkable premises in miRNAs is that they are many times upregulated in certain diseases. Therefore, the usage of specific blockers (i.e. antisense approaches) of the overexpressed mature microRNAs may be useful as therapeutic strategies to block their expression. Numerous methods have been used to inhibit miRNA repression of protein expression; however, each one is associated with RISC complex disruption. The most common method is the use of single-stranded antisense oligonucleotides sequences -antagomiRs (when cholesterol conjugated) -that are specifically designed to hybridize to corresponding mRNA and inhibit its function by disruption of ribosome assembly. Nevertheless, these antisense oligos possess weak intrinsic binding affinities and are readily degraded by nucleases. Besides, they are only designed to bind mature miRNAs and not messenger RNA, preventing the degradation of mRNA, and promoting its translation. In fact, in order to achieve effective miRNA silencing levels, the miRNA inhibition therapy needs that antisense oligos to carry chemical modifications [65] . These chemical modifications rely specially on the backbone chemistry and sugar moieties. In fact the phosphorothioate backbone modification is, to date, one of the most widely used modifications. However, chemical modifications are too expensive or inadequate [66] .
DNA plasmids, carrying the sequence for the miRNA coding gene, are typically used as substitutes of the RNA antisense oligos in order to overcome some of the instability problems.
In cases where the miRNAs expression is downregulated, exogenous mature miRNAs (known here as miRNA mimics) may be delivered to restore their expression and promote normal cell homeostasis, by a miRNA replacement therapy approach. However, the exogenous administration of single stranded miRNA mimics falls short of expectations. In fact, endogenous double stranded miRNAs have a 100
to 1000 fold higher potency compared to the exogenous ones [65] .
Targeting ectopically miRNAs may provide a vital diagnostic or therapeutic strategy for human cancer in the near future. In fact, both the antisense inhibition as the mature miRNA replacement therapies are valuable and have been considered as potentially treatment approaches (Figure 3 ) [67] . In any case, choosing the appropriate vehicle/vector to increase the delivery and the specificity of the miRNA seems to be one of the most important aspects influencing the activity of the miRNA. are negatively charged, making it difficult to cross the cell membrane, iii) weak protection against action by serum ribonucleases, iv) poor chemical stability, v) need for targeted delivery to specific tumor cells so as not to disrupt normal cells, and last but not least vi) difficulty in silencing multiple targets simultaneously, so as to avoid development of resistance to therapeutic agents [68] . Thus, the efficient delivery of RNA antisense and siRNA oligos or mature miRNAs is a huge bottleneck in miRNA delivery progress. Nanotechnology and nanoparticles (NPs) in particular can overcome some of these drawbacks offering a protective environment to RNA oligos and an efficient and biocompatible delivery vehicle for intracellular gene regulation.
Vectors for miRNA delivery
All of therapeutics must meet the same main challenge -developing a system capable of circulating in the blood stream undetected by the immune system and able to recognize the desirable target and signal it for effective drug delivery or gene silencing. In the past, modified viral vectors were found to be extremely efficient in gene delivery; however they are prompt to an extensive immune response impairing most of the proposed viral systems. Besides viral vectors, miRNA delivery in vitro is usually achieved using cholesterol conjugated 2'-O-methyl antisense oligonucleotides  the so called locked nucleic acid (LNAs) based antisense oligos. These LNAs are oligos with multiple miRNA binding sites that are recognized as competitive inhibitors or oligos complementary to miRNA binding sites [69] .
For in vivo miRNA delivery, the most traditional procedure is the administration of naked miRNAs, which results in liver accumulation. In fact, the ischemic injury or tumor vasculature delivery is found to be disappointing and challenging. Consequently, the use of nanomaterials for miRNA strategies is paving the way for miRNA sensing and delivery [65] .
The success of a gene therapy vector depends on three factors, 1) choosing an appropriate therapeutic gene, 2) the delivery of the therapeutic gene to as many diseased cells as possible, and 3) the accomplishment of a suitable level of gene expression. Several different approaches which preserve biocompatibility, selectivity and efficiency have been developed based on nonviral lipids or protein carriers, including cholesterol, metal NPs, liposomes, antibody promoter fusions, cyclodextrin NPs, fusogenic peptides, aptamers, biodegradable copolymers, and polymers [70] . Positively charged cationic liposomes and polymers, such as polyethylenimine (PEI), are currently the two major carriers used to complex with negatively charged oligonucleotides for systemic delivery [65, 71] .
Nanocarriers-mediated delivery: the necessity in cancer nanotheranostics
Cancer therapy is not a one-size-fits-all scenario, it must be adapted to each patient in a highly specific and selective way [72] . In fact, advances in cancer diagnosis and therapy have not been as effective as for other chronic diseases, and effective detection methods only exist for some types of cancer [18] .
Thus, the main challenge is to find new and more effective diagnostic agents for the monitoring of predictive cell molecular changes that are involved in tumor development. The key to the efficient and ultimately triumphant treatment of cancer is early and accurate diagnosis [73] .
Nanotechnology is here and can now be exploited for cancer theranostics (combination of diagnostics and therapy in one system using the benefits of nanotechnology) via the development of diagnostics systems such as colorimetric and immunoassays, and in therapy approaches through gene therapy, drug delivery and tumor targeting systems [74] [75] [76] . The use of nano-sized materials for diagnostics and therapy purposes is a promising field as more and improved techniques are becoming avai lable with increased sensitivity at lower costs, when compared to the traditional methods. An inspiration to science from the time of Faraday, today nanomaterials and nanoparticles are being used for an evergrowing number of biological applications. The high surface-to-volume ratio and size-dependent optical properties, of the nanoparticles make them interesting materials for their use in biomedical applications and are extremely attractive for cancer nanotheranostics [77] .
When referring to cancer therapy, targeting and localized delivery are of utmost importance in enhancing the therapeutic effect and decreasing undesirable distribution to healthy organs and tissues.
Multifunctional intelligent nanomaterials may potentiate the development of personalized cancer therapy based on the individual's biological information within the tumor (biomolecular profiling) [78] . In fact, nanomaterials are increasingly used as imaging agents and drug delivery vehicles because their tunable physical and chemical properties offer unique opportunities for developing new approaches to diagnose, prevent and treat diseases. The possibility to combine in one single device chemical and physical properties (i.e the bioactivity of a given compound bound to fluorescence, enabling self-tracking) and magnetism properties (allowing cell separation, heat generation), make nanoparticles unique multipurpose tools [75, 79, 80] .
Although there are technical challenges associated with the therapeutic application of nanomaterials, the integration of therapy with diagnostic profiling has accelerated the pace of discovery of new nanotechnology methods. The development of a safe, efficient, specific and nonpathogenic vehicle for gene delivery is highly attractive [81, 82] . This integration is fuelling biopharmaceutical research and development efforts by expanding and validating the pool of potential therapeutic targets, straining the already serious bottlenecks in drug discovery industry [83] .
Further research into the fundamental mechanisms of gene therapy using nanodevices could unveil new dimensions of nanoparticle-mediated gene silencing that will have profound implications for understanding gene regulation, and which could also affect the development of functional genomics and therapeutic applications.
Inorganic vs Organic DNA/RNA nanocarriers for cancer therapy
Suitable inorganic (quantum dots -QDs, gold, silica and magnetic nanoparticles) and organic (liposomes, lipids, dendrimers, micelles) nanocarriers can be used as nanovectors for miRNAs silencing and delivery (see Figure 4) . In fact, the nanocarrier delivery of therapeutic nucleic acids is highly desirable and constitutes an important challenge to gene therapy. The unique physico-chemical properties of both inorganic and organic nanocarriers show great potential of application in biomedicine for the development of sensing platforms and therapeutics [84] . Recent advances in approaches using nanocarriers functionalized with oligonucleotides have made them an attractive tool for DNA/RNA based therapy, where antisense RNA technology and miRNA sensing in particular shows a significant potential for gene regulation in therapeutics and in diagnostics [85, 86] .
Although the delivery of miRNAs by nanomaterials is recent and mostly used for in vitro applications, their use as miR vehicles has huge advantages. In fact, oligonucleotides such as anti-miRNA, antagomiRs, synthetic miRNA mimics and mature miRNAs can be conjugated to nanocarriers, protecting from nuclease degradation when compared to free/naked oligos. Moreover, immune stimulation and/or suppression associated with DNA/RNA nanocarriers is far more reduced than with the naked oligos [68] . Nevertheless, the size, charge, surface chemistry and hydrophobicity of the nanocarriers dictate their interaction with the immune system [87] . And the interaction of nanocarriers with the immune system determines the therapeutic efficiency of the delivered miRNA. Although numerous polymers can be used to avoid immunostimulation, PEGylation is still the most common use system to bypass the recognition of the phagocytic immune cells, increasing the circulation and lifetime inside the body by avoiding opsonization [88] . There are almost 100 reports published for the delivery of miRNAs in cancer using inorganic and organic nanocarriers; Cy3-Cyanine dye; LNA-lock nucleic acid; GD2-disialoganglioside; PLGA-poly(lactic-co-glycolic acid); PEIpolyethylenimine; VEGF-vascular endothelial growth factor; EGFR-Epidermal growth factor receptor. [111] One of the most used inorganic nanoparticles for miRNA delivery in cancer are the gold nanoparticle s (AuNPs) as they possess astonishing optical and electronic properties, well-regulated morphology and size dispersion, great stability and biological compatibility and easy surface functionalization. The main characteristics include the electrical, chemical, and optical properties. The optical properties of AuNPs are significant because its adsorption and emission of the wavelength are within the visible range of light and because of their size-and shape-dependent properties [112, 113] .
Concerning miRNA silencing and delivery systems using AuNPs, the majority uses the delivery of miRNAs that mediate efficient knockdown in functional reported gene assays (luciferase and GFP) and also apoptosis-inducing miRNAs, in vitro only. The only study reported so far concerning the use of AuNPs the detection in living cells at the same time as oncomiR inhibition occurs was reported by Figure 5) . The authors reported a gold nanoparticle-based nanobeacon (Aunanobeacon) as an innovative theranostic approach for detection and inhibition of sequence-specific miRNA in vitro [31] . The proposed method allows real-time detection of the beacon's signal while yielding a quantifiable fluorescence directly proportional to the level of gene silencing [31, [114] [115] [116] . The utmost common miRNA therapeutic approaches in cancer are the inhibition of oncomiRs (see Table 1 ) using either AuNPs or other inorganic nanoparticles (QDs and iron oxide). Silica NPs with cationic surfaces and modified/encapsulated with fluorescent fluorophores have been shown to be efficient gene transfection agents, protecting nucleic acids from enzymatic degradation [117] .
Conde et al. (see
An important finding when applying inorganic nanocarriers for miRNA is that very low concentrations of miRNA are required for target suppression [117] . Moreover, Natarajan and co-workers reported that 100 nM was the minimum miRNA concentration for maximum apoptosis induction [95] .
Concerning the organic vehicles, one of the most common nanocarriers for miRNA delivery are the liposome/lipid-based and the polymeric systems, especially the use of cationic lipids (cationic head group plus hydrophobic moiety bound to a linker) since strongly attached to nucleic acid phosphate groups [117] and cationic polymers (natural polymers -peptides, proteins, chitosan; or synthetic polymers-dendrimers, poly(lactic-co-glycolic acid, poly(L-lysine), polyethylenimine, collagen) [118] .
The majority of the organic nanocarriers use the delivery of tumor suppressor miRNAs for efficient in vivo miRNA replacement therapy, in lung, colorectal, liver and head and neck cancers. The major inconvenience of using cationic lipid and liposomal-based nanocarriers is the toxicity issue when administered in vivo [119] . Future surface passivation with long-circulating polymers (i.e.
Polyethylene glycol -PEG), hyaluronic acid (reduce immunogenicity) [120] , cholesterol (improve transfection, protects nucleic acids) or vitamin E (increase stability) [97] , as well as the optimization of formulation to clinical doses is imperative [117] .
Current challenges and future perspectives
Technical hurdles (sensitivity, stability, functionality and reliability) and potential solutions
At the beginning of this millennium an amazing genetic phenomenon was projected into the limelight and claimed by most as the most substantial research in years and the "gentlest art of shredding genes".
Its proposed mechanism was relatively simple and obeyed the law of common sense: introducing antisense RNA sequences into cells could inhibit the production of the protein encoded by the sense RNA strand. It was almost inconceivable that it could ever fail to succeed.
Except for a number of genes that failed to show sensitivity to antisense RNA, with sense RNA, used as a negative control in antisense RNA experiments, being as effective as antisense RNA (which seemed completely counter-intuitive), the most technical hurdles rely on the production of a delivery vehicle. In fact, only two miRNA candidates/vehicles, an inhibition therapy miR-22 antisense LNA (Santaris Pharma) and a replacement therapy liposome miR-34 mimic (Mirna Therapeutics, Inc.) have reached clinical trials [65] .
Opinions are divided as to the future of gene delivery. Some continue to argue that a generic version of nanoparticle-based drug delivery vehicle would solve all hurdles [121] , while others claim that a single system cannot be the answer for all diseases, as RNAi therapy approaches must consider the different cell/tissue/organ types [65] .
One thing is consensual -successful miRNA or RNAi therapeutic nanoparticle must guarantee the following (adapted from [65, [121] [122] [123] [124] While some disease types could benefit from systemic delivery of genes albeit following implementation of all of the above mentioned tactics for proper targeting and transfection, the field could benefit from utilizing available technologies developed for tissue engineering and controlled delivery systems for local drug administration. Yet, miRNA delivery via biomaterials scaffolding has been poorly applied to this technology. Once miRNAs are naturally players in controlling cell functions and differentiation processes, we therefore expect that miRNA delivery from scaffolds (eg.
Hydrogels [126] , biopolymers [127] , dendrimers [128] ) for inhibition or for replacement therapies will be highly adopted in future use not only for cancer but also for tissue engineering, while regeneration replacing or augmenting cell therapy [129] . The delivery of miRNAs from scaffolds provides a versatile method, for controlling stem cell differentiation and tissue functions and inflammation like extensively reported elsewhere [130, 131] , but especially to miRNA local administration to tumor milieu. A tissue-specific scaffold that locally deliver payload to the tumor with minimal inflammation and tissue toxicity, readily adjusted through manipulation of material type and formulation, would be the ideal scaffold biomaterial for local delivery or replacement of miRNAs.
Consequently, in order to build a scaffold platform to better support nanomaterials/nanoparticles for local delivery, a successful system must guarantee the following (adapted from [132] ):
i. Biodegradability. The main goal of the scaffold is to release their cargo into the xenografted tissue and over time, replace the implanted scaffold or tissue engineered construct. The scaffold must be somehow degradable in order to release their content to the target cells/tissues/organs. The secondary products of this degradation should be non-toxic and able to suffer normal body clearance. Usually to allow degradation within the target tissue a controlled inflammatory response and recruitment of inflammatory macrophages is required.
ii. Functionality. The scaffold must provide a matrix for normal cell adhesion, where they function normally and migrate on the surface and through the scaffold.
iii. Mechanical properties. In an ideal scenario the scaffold must have mechanical properties consistent with the anatomical site where is going to be implanted. It must be strong enough to allow handling but most important to be attached to the target site.
iv. Scaffold architecture. The architecture of scaffolds is of critical importance, once it should have an interconnected pore structure and high porosity to ensure cell adhesion and penetration, as well as appropriate diffusion of their cargo within the construct and to the extra-cellular environment (of a tumor tissue for example). In fact, a porous interconnected structure is required to allow diffusion of products out of the scaffold, for example nanoparticles carrying antisense oligos or mature miRNAs.
v.
Manufacturing technology.
A particular engineered scaffold must be cost effective and should allow for large scale-up production in order to be clinically and commercially feasible. The development of a scalable manufacturing process is essential to ensure successful translation to clinic.
Additionally, careful nanoparticle design is required to impart biosafety. Recent studies show that nanomaterials can either stimulate and/or suppress the immune responses, and their immunocompatibility is largely determined by their surface chemistry. In fact, particle size, solubility and surface modification largely determines its biocompatibility and hence applicability [87] (see Figure 6 ). There is not a simple solution to overcome biocompatibility issue. Even though there is not any general mechanism for making nanoparticles universally 'non-toxic' to all living cells and all organisms, there are important findings that can be applied for increasing nanoparticle biocompatibility (Adapted from [134, 135] ):
i. Using the lowest nanoparticle dose to get the desired response for the shortest period of time;
ii. Nanoparticle's coating: extremely important for stability but also for biocompatibility (a coat that completely covers the nanoparticle reactive surface may avoid complement or antibody attachment, or dissolution of the coating by cell digestion);
iii.
Always test nanoparticle/biological interactions experimentally (almost no importance is given when testing nanomaterials in the detection of genetic damages or in identifying protein markers of toxicity, or measuring the level of oxidative stress, see example [115] );
iv.
Modify the nanoparticles, if the biosafety test fail, in order to eliminate membrane lipid peroxidation, the generation of reactive oxygen species, acute and chronic release of inflammatory factors (and 'complement' activation), the possibility of nanoparticles becoming 'stuck' during filtration or passage through pores and fenestrations.
With all the features described above concerning nanoparticles and scaffolds design in mind, it is time to combine these two products using the well-studied gene delivery via nanoparticles, now embedded in a scaffold.
This combination may produce incredible two-and three-dimensional systems, which will provide essential key functions, such as (Adapted from [136] f) providing direct control of structure from the molecular to the macroscopic level.
Creating scaffolds and building blocks with the already optimized nanoparticle's systems will definitely provide unique tools for the creation of highly efficient catalysts, sensors, and devices, but especially for miRNAs (siRNAs or antisense oligos) delivery and specific chemotherapeutic drugsdelivery with stimuli-responsive surfaces and layer-by-layer construction [136] .
Final Conclusions
Over 800 human miRNAs have been discovered to date, emphasizing the importance of these effector molecules in human body and adding a new dimension to our understanding of complex gene regulatory networks. Understanding and exploiting new platforms for controlling their expression, by inhibition or replacement therapies is of urgent need. Consequently, nanotechnology and biomaterials have been gaining momentum in establishing solid knowledge in the development of new sensing and inhibition therapies using miRNAs in cancer. All the tools have been created. Incredible advances have occurred in the development of new nanovehicles capable of efficiently transporting miRNAs and antisense DNA or RNA oligonucleotides, especially in the systemic administration route. miRNA local delivery via biomaterials scaffolding needs added support and focus.
